Turn Therapeutics initiated with a Buy at D. Boral Capital

D. Boral Capital initiated coverage of Turn Therapeutics (TTRX) with a Buy rating and $8 price target Turn is developing a dermatology-focused therapeutic platform to address inflammatory and immune-mediated skin diseases with high unmet need, the analyst tells investors in a research note. The firm says the company has both near-term clinical readouts and longer-term expansion opportunities across dermatology and related inflammatory indications. Turn’s lead programs target conditions where current standards of care are limited by safety, tolerability, or inconsistent efficacy, contends D. Boral.